3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma SN

Smith & Nephew

SN LSE GB0009223206 Biotech & Pharma

Stock factsheet

TickerSN
ExchangeLSE
ISINGB0009223206
WKN
SectorBiotech & Pharma
Size class
Market capitalisation

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.

Company profile

Smith & Nephew is a British medical technology company that develops and markets orthopaedic implants, wound care products and endoscopy solutions. Its products are used in hospitals and clinics worldwide. The company operates across the segments of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Smith & NephewSN LSE
4DMEDICAL LIMITED 4DXASX
Abcam LSE
Accor ACEuronext Paris
Alexion Pharmaceuticals ALXNNASDAQ
Amicus Therapeutics FOLDNASDAQ
Ansell ANNASX

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.